Hepatitis Monthly

Published by: Kowsar

Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

Reza Karbasi-Afshar 1 and Amin Saburi 2 , 3 , *
Authors Information
1 Cardiovascular Diseases Department, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Baqiyatallah Research Center of Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2013, 13 (5); e8962
  • Published Online: May 14, 2013
  • Article Type: Letter
  • Received: November 5, 2012
  • Accepted: December 17, 2012
  • DOI: 10.5812/hepatmon.8962

To Cite: Karbasi-Afshar R, Saburi A. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C, Hepat Mon. 2013 ;13(5):e8962. doi: 10.5812/hepatmon.8962.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Almawardy R, Elhammady W, Mousa N, Abotaleb S. Is combination therapy for chronic hepatitis C toxic for cardiac function? Hepat Mon. 2012; 12(8)[DOI][PubMed]
  • 2. Demir M, Demir C. Effect of hepatitis C virus infection on the left ventricular systolic and diastolic functions. South Med J. 2011; 104(8): 543-6[DOI][PubMed]
  • 3. Maruyama S, Koda M, Oyake N, Sato H, Fujii Y, Horie Y, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2012; [DOI][PubMed]
  • 4. Terrier B, Karras A, Cluzel P, Collet JP, Sene D, Saadoun D, et al. Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. Am J Cardiol. 2012; [DOI][PubMed]
  • 5. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Hepat Mon. 2012; 12(9)[DOI]
  • 6. Perez-Alvarez R, Perez-Lopez R, Lombrana JL, Rodriguez M, Rodrigo L. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J Viral Hepat. 2002; 9(1): 75-9[PubMed]
  • 7. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011; 4(4): 425-32[DOI][PubMed]
  • 8. Che W, Liu W, Wei Y, Xu Y, Hou L, Matsumori A, et al. Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection. J Viral Hepat. 2012; 19(5): 327-31[DOI][PubMed]
  • 9. Dabrowska MM, Mikula T, Wiercinska-Drapalo A. HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients. Eur J Gastroenterol Hepatol. 2012; 24(11): 1308-12[DOI][PubMed]
  • 10. Osztovits J, Horvath E, Tax J, Csihi L, Horvath T, Littvay L, et al. Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection: Anti-HCV therapy and autonomic function. hepat Mon. 2011; 11(2): 114-8[PubMed]
  • 11. Choy-Shan A, Berezovskaya S, Zinn A, Sedlis SP, Bini EJ. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009; 21(12): 1438-40[DOI][PubMed]
  • 12. Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, et al. Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat. 2011; 18(7)-71[DOI][PubMed]
  • 13. Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, et al. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. Hepato-gastroenterol. 2011; 58(107-108): 875-9[PubMed]
  • 14. Payen JL, Pillard F, Mascarell V, Riviere D, Couzigou P, Kharlov N. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroenterol Clin Biol. 2009; 33(1 Pt 1): 8-14[DOI][PubMed]
  • 15. Yan Z, Fan K, Fan Y, Wang X, Mao Q, Deng G, et al. Thyroid Dysfunction in Chinese Patients with Chronic Hepatitis C Treated with Interferon Alpha: Incidence, Long-Term Outcomes and Predictive Factors. Hepat Mon. 2012; 12(9)[DOI]
  • 16. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010; 47(1): 72-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments